Skip to content

The effect of Plasmapheresis on hypoxia in patients suffering from COVID-19

The effect ofPlasmapheresis on hypoxia in patients suffering from COVID-19: A randomized clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220517054899N1
Enrollment
40
Registered
2022-08-13
Start date
2022-07-22
Completion date
Unknown
Last updated
2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corona virus (Covid-19). J12.81

Interventions

Intervention 1: Intervention group: Patients in the intervention group, in addition to the standard treatment of Covid-19, (dexamethasone at a dose of 6 mg per day and remedSivir at a dose of 200 mg o

Sponsors

Birjand University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Definitive diagnosis of Covid-19 based on taking a sample from the pharynx and PCR laboratory confirmation Lung involvement more than 50% SPO2 levels below 80% without oxygen or below 88% with oxygen or IL above 10 or ferritin above 1500 Patients who have not responded to other Covid-19 treatments Age over 18 years and consent to participate in the study

Exclusion criteria

Exclusion criteria: History of albumin sensitivity Heparin allergy who cannot receive heparin as an anticoagulant during plasmapheresis Patients with hypocalcemia (citrate used in the plasmapheresis process exacerbates hypocalcemia)

Design outcomes

Primary

MeasureTime frame
Percentage of blood oxygen saturation (SPO2). Timepoint: On days zero (before the intervention), days one, three, five and seven after the intervention. Method of measurement: Pulse oximeter Bitmos Gmbh made in Germany.;Arterial blood oxygen pressure in the analysis of blood gases Pao2. Timepoint: On days zero (before the intervention), days one, three, five and seven after the intervention. Method of measurement: Blood sample to measure blood gases.

Secondary

MeasureTime frame
Duration of hospitalization of the patient. Timepoint: End of hospitalization or death of the patient. Method of measurement: By day.;C-reactive protein (CRP) Factor. Timepoint: On days zero (before the intervention), days one, three, five and seven after the intervention. Method of measurement: Blood Test Prestige 24i machine made in Japan.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVajehallah Raeesi

Birjand University of Medical Sciences

vajehraeesi@yahoo.com+98 56 3162 2430

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026